Tuberculosis(TB) continues to be a global health threat.BCG was developed as an attenuated live vaccine for tuberculosis control nearly a century ago.Despite being the most widely used vaccine in human history,BCG is not an ideal vaccine and has two major limitations:its poor efficacy against adult pulmonary TB and its disconcerting safety in immunocompromised individuals.A safer and more effective TB vaccine is urgently needed.This review article discusses current strategies to develop the next generation of TB vaccines to replace BCG. While some progresses have been made in the past decade,significant challenges lie ahead.